EUVIMEDEUVIMED entdecken
Crossref

A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy

Qingxin Yao, Feng Lin, Chenghao Lu, Ruijia Zhang, Hanlin Xu, Xiaoqian Hu, Ziyang Wu, Yuan Gao iD, Peng R Chen iD

Bioconjugate Chemistry · 20.12.2023 · 34 (12) · 2255-2262

DOI: 10.1021/acs.bioconjchem.3c00404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 13.11.2023. Verfasst von Qingxin Yao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Laboratory of Biomedical Materials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, …. Hauptthemen laut MEDLINE: Prodrugs, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bioorthogonal prodrug therapies offer an intriguing two-component system that features enhanced circulating stability and controlled activation on demand. Current strategies often deliver either the prodrug or its complementary activator to the tumor with a monomechanism targeted mechanism, which cannot achieve the desired antitumor efficacy and safety profile. The orchestration of two distinct and orthogonal mechanisms should overcome the hierarchical heterogeneity of solid tumors to improve the delivery efficiency of both components simultaneously for bio-orthogonal prodrug therapies. We herein developed a dual-mechanism targeted bioorthogonal prodrug therapy by integrating two orthogonal, receptor-independent tumor-targeting strategies. We first employed the endogenous albumin transport system to generate the in situ albumin-bound, bioorthogonal-caged doxorubicin prodrug with extended plasma circulation and selective accumulation at the tumor site. We then employed enzyme-instructed self-assembly (EISA) to specifically enrich the bioorthogonal activators within tumor cells. As each targeted delivery mode induced an intrinsic pharmacokinetic profile, further optimization of the administration sequence according to their pharmacokinetics allowed the spatiotemporally controlled prodrug activation on-target and on-demand. Taken together, by orchestrating two discrete and receptor-independent targeting strategies, we developed an all-small-molecule based bioorthogonal prodrug system for dual-mechanism targeted anticancer therapies to maximize therapeutic efficacy and minimize adverse drug reactions for chemotherapeutic agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProdrugsNeoplasmsHumansDoxorubicinAlbuminsCell Line, Tumor

Substanzen

ProdrugsDoxorubicinAlbumins

Autor:innen und Institutionen

  • Beijing Laboratory of Biomedical Materials, College of Materials Science and Engineering, Beijing University of Chemical Technology, Beijing 100029, China.
  • Synthetic and Functional Biomolecules Center, Beijing National Laboratory for Molecular Sciences, Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education, College of Chemistry and Molec…
  • Peking-Tsinghua Center for Life Sciences, Peking University, Beijing 100871, China.
  • Chinese Academy of Sciences Key Laboratory of Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology, Beijing 100190, China.

ORCID-Profile: Yuan Gao, Peng R Chen

Förderung

  • National Key Research and Development Program of China
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China

Zitieren

APA

Yao, Q., Lin, F., Lu, C., Zhang, R., Xu, H., Hu, X., Wu, Z., Gao, Y., & Chen, P. R. (2023). A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy. Bioconjugate Chemistry, 34(12), 2255-2262. https://doi.org/10.1021/acs.bioconjchem.3c00404

Vancouver

Yao Q, Lin F, Lu C, Zhang R, Xu H, Hu X, et al. A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy. Bioconjugate Chemistry. 2023;34(12):2255-2262. doi:10.1021/acs.bioconjchem.3c00404

BibTeX
@article{Yao2023,
  author = {Yao, Qingxin and Lin, Feng and Lu, Chenghao and Zhang, Ruijia and Xu, Hanlin and Hu, Xiaoqian and Wu, Ziyang and Gao, Yuan and Chen, Peng R},
  title = {A Dual-Mechanism Targeted Bioorthogonal Prodrug Therapy},
  journal = {Bioconjugate Chemistry},
  year = {2023},
  volume = {34},
  number = {12},
  pages = {2255--2262},
  doi = {10.1021/acs.bioconjchem.3c00404}
}
Kostenlos starten →